A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer

BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. Human epidermal growth factor receptor 2 (HER2) amplification occurs in approximately 13–23% of all GC cases and patients with HER2 overexpression exhibit a poor prognosis. Lapatinib, a dual EGFR/HER2 ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Gang, Zhu, Qihui, Kang, Wonyoung, Lee, Hamin, Maher, Leigh, Suh, Yun-Suhk, Michaud, Michael, Silva, Mayerlin, Kwon, Jee Young, Zhang, Chengsheng, Lee, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366014/
https://www.ncbi.nlm.nih.gov/pubmed/34399705
http://dx.doi.org/10.1186/s12885-021-08283-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366014/
https://www.ncbi.nlm.nih.gov/pubmed/34399705
http://dx.doi.org/10.1186/s12885-021-08283-9

Ejemplares similares